Powered by

Proskauer Advises Celgene Corporation in Its Acquisition of Juno Therapeutics

Jan 22, 2018 - Business Wire

International law firm Proskauer represented longtime client Celgene Corporation (NASDAQ: CELG) in its definitive agreement to acquire Juno Therapeutics, Inc. (NASDAQ: JUNO). Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares).

Juno is a pioneer in the development of CAR (chimeric antigen rece...